IP Library Granted Patent US 10,758,511
Granted Patent B2
US 10,758,511 · App. 15/777,141 · Granted Sep 1, 2020

Stable analogs of CYP450 lipid metabolites and inhibitors of soluble epoxide hydrolase

Inventors: Kip M. Connor (Newton, MA); Eiichi Hasegawa (Fukuoka, JP); Bruce D. Hammock (Davis, CA); Kin Sing Stephen Lee (Davis, CA)
Assignees: Massachusetts Eye and Ear Infirmary; The Regents of the University of California
A61K31/336A61K9/0019A61K9/0048A61K31/17A61K31/202A61K31/445A61P27/02A61P27/04A61P27/06A61K31/4468A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,758,511
App. No.
15/777,141
Granted
Sep 1, 2020
Kind
B2
Abstract

This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).

Claims (7)

1. A method of treating or reducing the risk of an ophthalmological disorder associated with neovascularization, the method comprising administering to a subject in need thereof a therapeutically effective amount of an epoxydocosapentaenoic acid (EDP) or an epoxyeicosatetraenoic acid (EEQ), or a pharmaceutically acceptable salt thereof, and an effective amount of an inhibitor of a soluble epoxide hydrolase which is 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea having the following structure:

or a pharmaceutically acceptable salt thereof.

2. A method of treating or reducing the risk of an ophthalmological disorder associated with neovascularization, the method comprising administering to a subject in need thereof a therapeutically effective amount of:

an epoxymetabolite of a ω-3 long chain polyunsaturated fatty acid (LCPUFA) selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and

an inhibitor of a soluble epoxide hydrolase which is 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea having the following structure:

or a pharmaceutically acceptable salt thereof.

Assignments (3)
CONFIRMATORY LICENSE Recorded Sep 26, 2022
From: MASSACHUSETTS EYE AND EAR INFIRMARY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061208/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2019
From: CONNOR, KIP M.; HASEGAWA, EIICHI
To: MASSACHUSETTS EYE AND EAR INFIRMARY
Reel/Frame 049533/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2019
From: HAMMOCK, BRUCE D.; LEE, KIN SING STEPHEN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 049533/0285 →
Continuity (3)
Provisional Application 62365289 · Jul 21, 2016
Provisional Application 62256609 · Nov 17, 2015
Related Publication 20180325860A1 · Nov 15, 2018